In patient-derived xenograft (PDX) models, Lo et al. treated mice orally with IPI-926, a semi-synthetic analog of cyclopamin and small-molecule inhibitor of SMO, and showed a specific inhibition of ligand-dependent HH pathway and a significant decrease in tumor weight and volume [130]. This evidence concerns the gene SMO and neoplasm.